Serina Therapeutics updates leadership and bylaws
Serina Therapeutics, Inc. reported leadership and governance updates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Serina Therapeutics, Inc. reported leadership and governance updates. Its subsidiary, Serina Therapeutics (AL), Inc., promoted Srini Tenjarla, Ph.D., to Chief Technology Officer, increasing his annual base salary to $425,000, effective back to March 15, 2026. The Company also raised Chief Executive Officer Steve Ledger’s annual base salary to $500,000, effective as of September 9, 2024, and paid the retroactive amount in a lump sum in April 2026.
The Board approved amended and restated bylaws effective April 15, 2026. The bylaws add detailed provisions for appointing Co-Chairs of the Board, allowing a Chair or any Co-Chair to call special stockholder meetings and preside over Board and stockholder meetings, with each Co-Chair holding the same authority and powers, subject to coordination expectations.
8-K Event Classification
3 items: 5.02, 5.03, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
CTO base salary: $425,000 per year
CEO base salary: $500,000 per year
Bylaws adoption date: April 15, 2026
+2 more
5 metrics
CTO base salary
$425,000 per year
Annual base salary for Srini Tenjarla effective March 15, 2026
CEO base salary
$500,000 per year
Annual base salary for CEO Steve Ledger effective September 9, 2024
Bylaws adoption date
April 15, 2026
Amended and restated bylaws approved and adopted by the Board
CTO promotion date
April 20, 2026
Date Serina (AL) named Srini Tenjarla as Chief Technology Officer
Retroactive CEO pay timing
April 2026 lump sum
Retroactive portion of CEO base salary increase paid
Key Terms
amended and restated bylaws, Co-Chairs of the Board of Directors, special meetings of stockholders, Emerging growth company, +1 more
5 terms
amended and restated bylaws regulatory
"the Board of Directors of the Company approved and adopted amended and restated bylaws of the Company"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
Co-Chairs of the Board of Directors regulatory
"The Bylaws include provisions relating to the appointment of Co-Chairs of the Board of Directors"
special meetings of stockholders regulatory
"clarifying that special meetings of stockholders may be called by the Chair or any Co-Chair"
Special meetings of stockholders are gatherings called outside the regular annual meeting to vote on specific, often urgent matters such as mergers, major asset sales, or changes in board control. For investors these meetings matter because they can produce quick, binding decisions that affect a shareholder’s ownership value or control rights—think of it like an emergency family meeting to decide whether to sell the house, where the outcome directly changes everyone’s stake.
Emerging growth company regulatory
"Emerging growth company o o Item 5.02."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive leadership change did Serina Therapeutics (SER) announce?
Serina Therapeutics’ subsidiary promoted Srini Tenjarla, Ph.D., to Chief Technology Officer. He previously served as Senior Vice President of CMC and Formulation since July 2024, reflecting an internal advancement in technical leadership at the company’s Serina Therapeutics (AL), Inc. unit.
How did Serina Therapeutics (SER) change CTO compensation?
In connection with his promotion to Chief Technology Officer, Srini Tenjarla’s annual base salary was set at $425,000. The new salary is effective retroactively to March 15, 2026, increasing his compensation from his prior role as Senior Vice President of CMC and Formulation.
What is the new base salary for Serina Therapeutics (SER) CEO?
Serina Therapeutics increased Chief Executive Officer Steve Ledger’s annual base salary to $500,000. The raise became effective as of September 9, 2024, under his employment agreement after certain strategic goals were satisfied, with the retroactive portion paid in a lump sum in April 2026.
Why did Serina Therapeutics (SER) increase its CEO’s salary retroactively?
The CEO’s salary increase was triggered under Steve Ledger’s employment agreement upon satisfying certain strategic goals. As a result, his $500,000 annual base salary is effective from September 9, 2024, and the company paid the retroactive difference in a lump-sum payment during April 2026.
What changes did Serina Therapeutics (SER) make to its bylaws?
The Board adopted amended and restated bylaws on April 15, 2026, adding provisions for appointing Co-Chairs of the Board. The updates clarify that a Chair or any Co-Chair may call special stockholder meetings, preside at meetings, and hold equal authority and powers with coordination expectations.
How do the new Co-Chair provisions affect Serina Therapeutics (SER) governance?
Under the amended bylaws, each Co-Chair has the same authority and powers as the Chair of the Board. A Chair or any Co-Chair may independently call special stockholder meetings and preside over Board or stockholder meetings, subject to coordination expectations detailed in the bylaws.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates